<DOC>
	<DOCNO>NCT02079844</DOCNO>
	<brief_summary>The purpose study determine whether cognitive impairment associate schizophrenia attenuate add-on roflumilast administration second generation antipsychotic ( SGA ) participant stable schizophrenia .</brief_summary>
	<brief_title>Roflumilast Plus Antipsychotics Proof Mechanism Study Schizophrenia</brief_title>
	<detailed_description>The drug test study call roflumilast . Roflumilast test add-on treatment second generation antipsychotic ( SGA ) treat cognitive impairment people stable schizophrenia . This study look improvement cognitive impairment associate schizophrenia people take roflumilast add-on SGA . The study enroll approximately 22 participant . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) All participant receive follow treatment different period throughout study : - Roflumilast Dose A + SGA - Roflumilast Dose B +SGA - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient + SGA . All participant ask take one tablet time day throughout study . This single-centre trial conduct United Kingdom . The overall time participate study 64 day . Participants make 2 screen visit clinic must bring clinic every day dose 3 Treatment Periods . Each Treatment Period 8 day duration . All participant also make 1 final visit 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Meets schizophrenia criterion define Diagnostic Statistical Manual Mental Disorders ( DSMV ) Mini International Neuropsychiatric Interview ( MINI ) . 4 . On stable dose second generation antipsychotic ( SGA ) least 2 month document medical history assess site staff . 5 . Meets follow symptom criterion : ( ) Positive Negative Syndrome Scale ( PANSS ) Conceptual Disorganization item score ≤4 ( b ) PANSS Hallucinatory Behavior Unusual Thought Content item score ≤4 ( c ) PANSS Negative Subscale score item ≤4 . 6 . Has cognitive impairment per investigator judgment . 7 . Is age 18 55 year , inclusive , time informed consent . 8 . Weighs least 60 kg body mass index ( BMI ) 18 32 kg/m^2 inclusive Screening . 9 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 10 . A female participant childbearing potential sexually active nonsterilized male partner agree use acceptable method contraception signing inform consent throughout duration study 12 week last dose . 11 . Has clinical laboratory evaluation ( include clinical chemistry , hematology complete urinalysis ) within reference range test laboratory , unless result deem clinically significant ( NCS ) investigator screen Day 1 Period 1 . 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Has receive roflumilast previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has uncontrolled , clinically significant neurological , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality may impact ability participant participate potentially confound study result . 5 . History claustrophobia inability tolerate mock scanner environment habituation/screening session . 6 . Fulfillment magnetic resonance imaging ( MRI ) contraindication standard radiography screening questionnaire Centre Neuroimaging Sciences , Institute Psychiatry , King 's College London ( ie , history surgery involve metal implant , metal body piercing , denture , dental plate bridge , implanted device electrically , magnetically , mechanically activate ) . 7 . Has know hypersensitivity component formulation roflumilast . 8 . Has positive urine drug result drug abuse Screening Day 1 treatment period . 9 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 6 month prior screen visit unwilling agree abstain alcohol drug throughout study . 10 . The participant history last year currently receive treatment clozapine . 11 . Has take exclude medication , supplement , food product . 12 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 13 . Has evidence current cardiovascular , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take roflumilast similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 14 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis frequent occurrence [ per week ] heartburn ) . 15 . History surgical intervention know impact absorption ( eg , bariatric surgery bowel resection ) . 16 . Has history cancer within past 5 year prior first dose study medication . This criterion include participant basal cell stage I squamous cell carcinoma skin eligible . 17 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) , human immunodeficiency virus ( HIV ) antibody/antigen Screening . 18 . Has poor peripheral venous access . 19 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 3 month prior Day 1 . 20 . Has Screening Day 1 Period 1 abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator . 21 . Has abnormal Screening Day 1 Period 1 laboratory value suggest clinically significant underlying disease participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 upper limit normal . 22 . Has abnormal Screening Day 1 Period 1 vital sign value suggest clinically significant underlying disease . 23 . Has risk suicide accord Investigator 's clinical judgment ( eg , per ColumbiaSuicide Severity Rating Scale [ CSSRS ] make suicide attempt within 6 month prior screen visit ) . 24 . Has current diagnosis significant psychiatric illness schizophrenia , per DSMV acute phase/episode . 25 . In opinion investigator sponsor , participant unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>